Drug Development
Infigratinib topped “even the most optimistic expectations” for efficacy and safety in the late-stage PROPEL 3 study in achondroplasia, Truist Securities analysts said Thursday.
FEATURED STORIES
Analysts, investors and scientists are eager for Biogen’s 2026 BIIB080 readout. Even if successful, executives warn that there are many more steps before the Alzheimer’s therapy could reach the market.
With a clutch of key data and planned regulatory applications this year from Avidity Biosciences, REGENXBIO and Capricor Therapeutics, CureDuchenne CSO Michael Kelly sees “momentum” in the Duchenne muscular dystrophy pipeline, as Sarepta’s Elevidys leaves the door open.
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
An announcement lit up the global grapevine today as Clene Nanomedicine released the results from Phase II of their RESCUE-ALS clinical trial.
In November 2019, Emory realized this experimental drug could have significant potential in respiratory viruses such as COVID-19.
The drug makers have until February 28, 2022 to review their findings and analytical processes for the drug they are developing to treat relapsed and/or refractory multiple myeloma.
The Centers for Disease Control and Prevention’s vaccine advisory committee meets today to discuss authorizing the Pfizer-BioNTech vaccine in children aged 5 to 11 years.
This novel diagnostic technology uses augmented reality and a smartphone or tablet to administer cognitive and functional tests.
Centessa showed positive early results from its Phase I Part B study on a potential drug that could direct mutation activity in patients with a particular gene that can cause liver and lung diseases.
The decision made VUITY the very first and only eye drop to be approved for the Presbyopia treatment. Follow the article to know aspects of this new treatment.
The FDA informed Moderna that it would need more time to evaluate the company’s Emergency Use Authorization (EUA) submission for its COVID-19 vaccine for adolescents 12 to 17 years of age.
Inovio shares are down about 2% in premarket trading after cancellation reports of a DNA cancer vaccine collab with AstraZeneca.
Researchers found that those who took either the once-a-month or once-every-two-month doses experienced longer periods before relapsing.